Sign the Resolution for a Federal
Commission on Drug Policy Sign the Resolution for a Federal
Commission on Drug Policy
Contents | Feedback | Search | DRCNet Home Page | Join DRCNet
DRCNet Library | Schaffer Library | Hemp (Marijuana) | Medical Information
Wayne Hall, Nadia Solowij and Jim Lemon, National Drug and Alcohol Research Centre
Prepared for the National Task Force on Cannabis
Acknowledgments
Executive summary
1. Summary of report
2. Introduction
3. Evidential principles
4. Cannabis the drug
5. The acute effects of cannabis intoxication
6. The chronic effects of cannabis use on health
7. The psychological effects of chronic cannabis use
8. The therapeutic effects of cannabinoids
9. An overall appraisal of the health and psychological effects of
cannabis
A full copy of the text version of this report can be obtained here.
The authors would like to acknowledge the assistance of the following people in the preparation of this manuscript:
Dr Robert Ali, Chairman of the National Task Force on Cannabis, for his encouragement and support at all stages of the project, and the members of the Task Force for their feedback on earlier drafts of the document.
Dr Mario Argandona (WHO Programme on Substance Abuse), Dr Greg Chesher, (National Drug and Alcohol Research Centre), Paul Christie, (Project Officer, National Task Force on Cannabis), Dr Bill Corrigal (Senior Scientist, Addiction Research Foundation, Toronto), Emeritus Professor Harold Kalant (Department of Pharmacology, University of Toronto), and Dr Jean-Marie Ruel (Bureau of Dangerous Drugs, Health and Welfare Canada) for their useful comments on the whole manuscript.
The following persons are acknowledged for their expert comments on specific sections of the manuscript: Dr Peter Fried (Carleton University, Ottawa, Ontario) for his comments on reproductive effects; Dr Richard Mattick (National Drug and Alcohol Research Centre) for his comments on the dependence syndrome; Dr Peter Nelson (Southern Cross University, New South Wales) for his comments on psychological effects); Dr Mehdi Paes (Department of Psychiatry, University of Rabat, Morocco) and Professor S.M. Channabasavanna (Director, National Institute of Mental Health and NeuroSciences, Bangalore, India) for their comments on psychiatric disorders; and Professor Donald Tashkin (Division of Pulmonary and Critical Care Medicine, University of California, Los Angeles Medical School) for his comments on cardiovascular and respiratory effects.
Eva Congreve, the Archivist at the National Drug and Alcohol Research Centre, performed above and beyond the call of duty in uncomplainingly and efficiently dealing with a plethora of requests for obscure publications in esoteric journals. Without her assistance, this review would not have been half as comprehensive as we hope it has been. Peter Congreve and Keith Warren collected articles and books which made the task of reading and writing easier.
Acknowledgment is given to the Centre's secretaries, Libby Barron, Margaret Eagers and
Gail Merlin, who undertook the thankless task of checking the referencing and proof
reading the manuscript.
The following is a summary of the major adverse health and psychological effects of
acute and chronic cannabis use, grouped according to the degree of confidence in the view
that the relationship between cannabis use and the adverse effect is a causal one.
anxiety, dysphoria, panic and paranoia, especially in naive users;
cognitive impairment, especially of attention and memory, for the duration of
intoxication;
psychomotor impairment, and probably an increased risk of accident if an intoxicated
person attempts to drive a motor vehicle, or operate machinery;
an increased risk of experiencing psychotic symptoms among those who are vulnerable
because of personal or family history of psychosis;
an increased risk of low birth weight babies if cannabis is used during pregnancy.
The major health and psychological effects of chronic heavy cannabis use, especially daily use over many years, remain uncertain. On the available evidence, the major probable adverse effects appear to be:
respiratory diseases associated with smoking as the method of administration, such as
chronic bronchitis, and the occurrence of histopathological changes that may be precursors
to the development of malignancy.
development of a cannabis dependence syndrome, characterised by an inability to abstain
from or to control cannabis use;
subtle forms of cognitive impairment, most particularly of attention and memory, which
persist while the user remains chronically intoxicated, and may or may not be reversible
after prolonged abstinence from cannabis.
The following are the major possible adverse effects of chronic, heavy cannabis use which remain to be confirmed by further research:
an increased risk of developing cancers of the aerodigestive tract, i.e. oral cavity,
pharynx, and oesophagus;
an increased risk of leukemia among offspring exposed while in utero;
a decline in occupational performance marked by underachievement in adults in occupations
requiring high level cognitive skills, and impaired educational attainment in adolescents;
birth defects occurring among children of women who used cannabis during their
pregnancies.
Adolescents with a history of poor school performance may have their educational
achievement further limited by the cognitive impairments produced by chronic intoxication
with cannabis.
Adolescents who initiate cannabis use in the early teens are at higher risk of progressing
to heavy cannabis use and other illicit drug use, and to the development of dependence on
cannabis.
Women of childbearing age
Pregnant women who continue to smoke cannabis are probably at increased risk of giving
birth to low birth weight babies, and perhaps of shortening their period of gestation.
Women of childbearing age who smoke cannabis at the time of conception or while pregnant
possibly increase the risk of their children being born with birth defects.
Persons with a number of pre-existing diseases who smoke cannabis are probably at an
increased risk of precipitating or exacerbating symptoms of their diseases. These include:
individuals with cardiovascular diseases, such as coronary artery disease, cerebrovascular
disease and hypertension;
individuals with respiratory diseases, such as asthma, bronchitis, and emphysema;
individuals with schizophrenia, who are at increased risk of precipitating or of
exacerbating schizophrenic symptoms;
individuals who are dependent on alcohol and other drugs, who are probably at an increased
risk of developing dependence on cannabis.
The health risks of alcohol, tobacco and cannabis use
Alcohol. The major risks of acute cannabis use are similar to the acute risks of alcohol intoxication in a number of respects. First, both drugs produce psychomotor and cognitive impairment. The impairment produced by alcohol increases risks of various kinds of accident. It remains to be determined whether cannabis intoxication produces similar increases in accidental injury and death, although on balance it probably does. Second, substantial doses of alcohol taken during the first trimester of pregnancy can produce a foetal alcohol syndrome. There is suggestive but far from conclusive evidence that cannabis used during pregnancy may have similar adverse effects. Third, there is a major health risk of acute alcohol use that is not shared with cannabis. In large doses alcohol can cause death by asphyxiation, alcohol poisoning, cardiomyopathy and cardiac infarct whereas there are no recorded cases of fatalities attributable to cannabis.
Tobacco. The major acute health risks that cannabis share with tobacco are the irritant
effects of smoke upon the respiratory system, and the stimulating effects of both THC and
nicotine on the cardiovascular system, both of which can be detrimental to persons with
cardiovascular disease.
Alcohol. Chronic cannabis use may share some of the risks of heavy chronic alcohol use.
First, heavy use of either drug increases the risk of developing a dependence syndrome in
which users experience difficulty in stopping or controlling their use. There is strong
evidence for such a syndrome in the case of alcohol and reasonable evidence in the case of
cannabis. Second, there is reasonable clinical evidence that the chronic heavy use of
alcohol can produce psychotic symptoms and psychoses in some individuals. There is
suggestive evidence that chronic heavy cannabis use may produce a toxic psychosis,
precipitate psychotic illnesses in predisposed individuals, and exacerbate psychotic
symptoms in individuals with schizophrenia. Third, there is good evidence that chronic
heavy alcohol use can indirectly cause brain injury - the Wernicke-Korsakov syndrome -
with symptoms of severe memory defect and an impaired ability to plan and organise.
Chronic cannabis use does not produce cognitive impairment of comparable severity but
there is suggestive evidence that chronic cannabis use may produce subtle defects in
cognitive functioning, that may or may not be reversible after abstinence. Fourth, there
is reasonable evidence that chronic heavy alcohol use produces impaired occupational
performance in adults and lowered educational achievements in adolescents. There is at
most suggestive evidence that chronic heavy cannabis use produces similar, albeit more
subtle impairments in occupational and educational performance of adults. Fifth, there is
good evidence that chronic, heavy alcohol use increases the risk of premature mortality
from accidents, suicide and violence. There is no comparable evidence for chronic cannabis
use, although it is likely that dependent cannabis users who frequently drive while
intoxicated with cannabis increase their risk of accidental injury or death. Sixth,
alcohol use has been accepted as a contributory cause of cancer of the oropharangeal
organs in men and women. There is suggestive evidence that chronic cannabis smoking may
also be a contributory cause of cancers of the aerodigestive tract (i.e. the mouth,
tongue, throat, oesophagus, lungs).
Tobacco. The major adverse health effects shared by chronic cannabis and tobacco smokers
are chronic respiratory diseases, such as chronic bronchitis, and probably, cancers of the
aerodigestive tract. The increased risk of cancer in the respiratory tract is a
consequence of the shared route of administration by smoking. It is possible that chronic
cannabis smoking also shares the cardiotoxic properties of tobacco smoking, although this
possibility remains to be investigated.
Contents | Feedback | Search | DRCNet Home Page | Join DRCNet
DRCNet Library | Schaffer Library | Hemp (Marijuana) | Medical Information